Leiby J M, Unverfurth D V, Neidhart J A
Cancer Treat Rep. 1986 Jul;70(7):899-901.
Eighteen women with metastatic breast cancer entered a phase I-II study of high-dose mitoxantrone (MXT). They were heavily pretreated (mean, 2.3 prior regimens) with drugs including both doxorubicin (14 patients) and MXT at usual doses (three). Doses studied were 16, 20, 25, and 30 mg/m2, repeated every 3-4 weeks. Marked leukopenia was seen at all dose levels (four episodes of infection were successfully treated). Fatigue and malaise were the most common nonhematologic toxic effects. At 25 mg/m2, six of 13 courses resulted in severe fatigue and malaise. MXT is tolerated at doses up to 25 mg/m2 every 3-4 weeks. Cardiac function must be closely monitored. No responses were seen in these heavily pretreated patients.
18名转移性乳腺癌女性患者进入了一项高剂量米托蒽醌（MXT）的I-II期研究。她们此前接受过多种药物的大量预处理（平均2.3种先前治疗方案），其中包括阿霉素（14例患者）和常规剂量的MXT（3例）。研究的剂量为16、20、25和30mg/m²，每3 - 4周重复一次。在所有剂量水平均观察到明显的白细胞减少（4例感染发作得到成功治疗）。疲劳和不适是最常见的非血液学毒性反应。在25mg/m²剂量时，13个疗程中有6个导致严重的疲劳和不适。米托蒽醌每3 - 4周以高达25mg/m²的剂量给药时耐受性良好。必须密切监测心脏功能。在这些经过大量预处理的患者中未观察到缓解情况。
